Cargando…

Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia

BACKGROUND: Glycemic variability (GV) has only been sparsely studied in patients with community-acquired pneumonia (CAP). This study aimed to quantify in-hospital GV in CAP patients, including determining the impact of type 2 diabetes mellitus (T2DM) and glucocorticoid (GC) treatment on GV. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Mikkel Thor, Dungu, Arnold Matovu, Klarskov, Carina Kirstine, Jensen, Andreas Kryger, Lindegaard, Birgitte, Kristensen, Peter Lommer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905566/
https://www.ncbi.nlm.nih.gov/pubmed/35264139
http://dx.doi.org/10.1186/s12890-022-01874-7
_version_ 1784665214885560320
author Olsen, Mikkel Thor
Dungu, Arnold Matovu
Klarskov, Carina Kirstine
Jensen, Andreas Kryger
Lindegaard, Birgitte
Kristensen, Peter Lommer
author_facet Olsen, Mikkel Thor
Dungu, Arnold Matovu
Klarskov, Carina Kirstine
Jensen, Andreas Kryger
Lindegaard, Birgitte
Kristensen, Peter Lommer
author_sort Olsen, Mikkel Thor
collection PubMed
description BACKGROUND: Glycemic variability (GV) has only been sparsely studied in patients with community-acquired pneumonia (CAP). This study aimed to quantify in-hospital GV in CAP patients, including determining the impact of type 2 diabetes mellitus (T2DM) and glucocorticoid (GC) treatment on GV. METHODS: This is a prospective cohort study of CAP patients (N = 40) with or without T2DM and treated or not with GCs. The primary endpoint was GV measured as glucose standard deviation (SD), coefficient of variation (CV), and postprandial glucose excursions (PPGE) based on continuous glucose monitoring (CGM). Analysis of glucose data was split into daytime and nighttime when possible. RESULTS: Patients included had a mean age of 74 (range 55 to 91) years. SD (95%CI) increased by a factor of 1.93 (1.40 to 2.66) and 2.29 (1.38 to 3.81) in patients with T2DM and not treated with GCs during the daytime and the nighttime, respectively (both P < 0.01), and by a factor of 1.42 (1.04 to 1.97) in patients treated with GCs but without T2DM during the daytime (P = 0.031) compared to patients without T2DM and not treated with GCs. CV (95%CI) increased by 5.1 (0.0 to 10.1) and 8.1 (1.0 to 15.2) percentage points during the daytime and the nighttime, respectively, in patients with T2DM and not treated with GCs compared to patients without T2DM and not treated with GCs (P = 0.046 and P = 0.026, respectively). PPGE (95% CI) increased during lunch by 2.5 (0.7 to 4.3) mmol/L (45 (13 to 77) mg/dL) in patients with T2DM and treated with GCs compared to patients without T2DM and not treated with GCs (P = 0.018). CONCLUSIONS: CAP patients receiving GCs, especially those with T2DM, are at great risk of developing high GV and therefore require clinical attention to mitigate GV. This applies particularly during the daytime. Results support the 1 to 2-h post-lunch screening procedure for glucocorticoid-induced hyperglycemia in patients without diabetes. SD was positively correlated with hospital length of stay. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-01874-7.
format Online
Article
Text
id pubmed-8905566
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89055662022-03-09 Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia Olsen, Mikkel Thor Dungu, Arnold Matovu Klarskov, Carina Kirstine Jensen, Andreas Kryger Lindegaard, Birgitte Kristensen, Peter Lommer BMC Pulm Med Research BACKGROUND: Glycemic variability (GV) has only been sparsely studied in patients with community-acquired pneumonia (CAP). This study aimed to quantify in-hospital GV in CAP patients, including determining the impact of type 2 diabetes mellitus (T2DM) and glucocorticoid (GC) treatment on GV. METHODS: This is a prospective cohort study of CAP patients (N = 40) with or without T2DM and treated or not with GCs. The primary endpoint was GV measured as glucose standard deviation (SD), coefficient of variation (CV), and postprandial glucose excursions (PPGE) based on continuous glucose monitoring (CGM). Analysis of glucose data was split into daytime and nighttime when possible. RESULTS: Patients included had a mean age of 74 (range 55 to 91) years. SD (95%CI) increased by a factor of 1.93 (1.40 to 2.66) and 2.29 (1.38 to 3.81) in patients with T2DM and not treated with GCs during the daytime and the nighttime, respectively (both P < 0.01), and by a factor of 1.42 (1.04 to 1.97) in patients treated with GCs but without T2DM during the daytime (P = 0.031) compared to patients without T2DM and not treated with GCs. CV (95%CI) increased by 5.1 (0.0 to 10.1) and 8.1 (1.0 to 15.2) percentage points during the daytime and the nighttime, respectively, in patients with T2DM and not treated with GCs compared to patients without T2DM and not treated with GCs (P = 0.046 and P = 0.026, respectively). PPGE (95% CI) increased during lunch by 2.5 (0.7 to 4.3) mmol/L (45 (13 to 77) mg/dL) in patients with T2DM and treated with GCs compared to patients without T2DM and not treated with GCs (P = 0.018). CONCLUSIONS: CAP patients receiving GCs, especially those with T2DM, are at great risk of developing high GV and therefore require clinical attention to mitigate GV. This applies particularly during the daytime. Results support the 1 to 2-h post-lunch screening procedure for glucocorticoid-induced hyperglycemia in patients without diabetes. SD was positively correlated with hospital length of stay. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-01874-7. BioMed Central 2022-03-09 /pmc/articles/PMC8905566/ /pubmed/35264139 http://dx.doi.org/10.1186/s12890-022-01874-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Olsen, Mikkel Thor
Dungu, Arnold Matovu
Klarskov, Carina Kirstine
Jensen, Andreas Kryger
Lindegaard, Birgitte
Kristensen, Peter Lommer
Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia
title Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia
title_full Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia
title_fullStr Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia
title_full_unstemmed Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia
title_short Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia
title_sort glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905566/
https://www.ncbi.nlm.nih.gov/pubmed/35264139
http://dx.doi.org/10.1186/s12890-022-01874-7
work_keys_str_mv AT olsenmikkelthor glycemicvariabilityassessedbycontinuousglucosemonitoringinhospitalizedpatientswithcommunityacquiredpneumonia
AT dunguarnoldmatovu glycemicvariabilityassessedbycontinuousglucosemonitoringinhospitalizedpatientswithcommunityacquiredpneumonia
AT klarskovcarinakirstine glycemicvariabilityassessedbycontinuousglucosemonitoringinhospitalizedpatientswithcommunityacquiredpneumonia
AT jensenandreaskryger glycemicvariabilityassessedbycontinuousglucosemonitoringinhospitalizedpatientswithcommunityacquiredpneumonia
AT lindegaardbirgitte glycemicvariabilityassessedbycontinuousglucosemonitoringinhospitalizedpatientswithcommunityacquiredpneumonia
AT kristensenpeterlommer glycemicvariabilityassessedbycontinuousglucosemonitoringinhospitalizedpatientswithcommunityacquiredpneumonia